The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its ...

Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...